Skip to main content
S&P 5007,676.77+0.70%DOW52,361.58+0.28%NASDAQ26,169.38+0.82%BTC$80,129.00+0.25%ETH$2,324.65+0.23%GOLD$4,027.20-0.28%OIL$101.22-0.53%
Smart Investors Daily
SID Premium
CA

NASDAQ · CADL

Candel Therapeutics, Inc.

Healthcare · Biotechnology

$7.79

Down-$0.24 (-2.99%)

Updated Oct 27, 2026, 2:50 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
355.76M
P/E ratio
-30.96
Dividend yield
0.00%
52-week range
$4.44 – $14.00
Volume
849.3K
Avg. volume
778.62K

Price performance · CADL

CADL price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 26, 2026

CADL closed at $7.79 after 21 trading sessions, down 30.38% for the selected period.

Last close
$7.79
Period change
-30.38%
Period low
$7.79
Period high
$11.19
Daily close
View OHLC price history
CADL OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 26, 2026$8.44$8.44$7.70$7.79849.3K
Oct 23, 2026$8.33$8.33$7.905$8.031.18M
Oct 22, 2026$8.45$8.79$8.255$8.38762.58K
Oct 21, 2026$8.65$8.82$8.35$8.371.1M
Oct 20, 2026$8.17$8.84$8.125$8.641.13M
Oct 19, 2026$8.37$8.4994$7.96$8.211.28M
Oct 16, 2026$8.92$8.92$8.125$8.191.51M
Oct 15, 2026$9.01$9.0999$8.79$8.91989.34K
Oct 14, 2026$9.06$9.43$9.03$9.07989.44K
Oct 13, 2026$9.78$9.845$9.22$9.271.13M
Oct 12, 2026$10.00$10.18$9.71$9.78744.63K
Oct 9, 2026$9.69$9.95$9.59$9.94718.37K
Oct 8, 2026$9.70$9.755$9.45$9.66888.5K
Oct 7, 2026$9.75$9.945$9.60$9.82714.95K
Oct 6, 2026$10.32$10.40$9.85$9.87977.77K
Oct 5, 2026$10.27$10.45$9.94$10.23980.89K
Oct 2, 2026$10.29$10.37$10.03$10.18878.8K
Oct 1, 2026$10.72$10.72$10.16$10.161.04M
Sep 30, 2026$11.02$11.245$10.37$10.441.27M
Sep 29, 2026$11.25$11.25$10.57$10.88963.29K
Sep 28, 2026$10.98$11.52$10.76$11.19771.02K

Latest CADL news

The latest Smart Investors Daily articles mentioning CADL.

Stock researchCompany · Overview

CADL research

Overview

Company profile and research snapshot.

Company profile

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$15.00
Implied upside
—
Analysts
14
CADL recent ratings
DateFirmRatingTarget
Oct 22, 2026JefferiesBuy—
Sep 21, 2026B of A SecuritiesBuy—
Aug 14, 2026B of A SecuritiesNeutral—
Aug 13, 2026HC Wainwright & Co.Buy—
Jul 13, 2026StifelBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Candel Therapeutics to Present at the SITC 2026 Annual Meeting

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical

Yahoo · Oct 1, 2026

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on September 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to 4 new employees, stock options to purchase an aggregate of 85,900 shares of the Company’s common stock, with a pe

Yahoo · Oct 1, 2026

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Peer-reviewed publication in Journal for ImmunoTherapy of Cancer reports median overall survival of 24.5 months in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI) NEEDHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today a

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By